NCT00193440View on ClinicalTrials.gov

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

April 30, 2004

Study Completion Date

January 31, 2009

Conditions
Non-Hodgkins Lymphoma
Interventions
DRUG

Rituximab

DRUG

CHOP

DRUG

CVP

DRUG

Ibritumomab Tiuxetan

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00193440 - Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter